Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 3 Recruiting NIH
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
- City of Hope Antelope Valley — Lancaster, California
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente-Fontana — Fontana, California
- Kaiser Permanente South Bay — Harbor City, California
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in California: - Providence Medical Foundation-Oncology ( Site 0168) — Fullerton, California
- MemorialCare Health System - Long Beach Medical Center ( Site 9559) — Long Beach, California
- Cancer Blood and Specialty Clinic ( Site 0109) — Los Alamitos, California
- Cedars-Sinai Medical Center ( Site 0115) — Los Angeles, California
- Pacific Hematology Oncology Associates ( Site 0131) — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in California: - Kaiser Permanente Southern California — Irvine, California
- University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- UCLA Department of Medicine Hematologyoncology — Los Angeles, California
- Kaiser Permanente Oakland Medical Center — Oakland, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in California: - Ucsf Fresno — Fresno, California
- Kaiser Permanente Southern California — Irvine, California
Phase 3 Recruiting Industry
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles (UCLA) — Los Angeles, California
- University of California, Irvine — Orange, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in California: - MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in California: - Hoag Hospital Newport Beach — Newport Beach, California
- University of California, Irvine Health — Orange, California
Phase 3 Recruiting Industry
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primar…
Sponsor: Kite, A Gilead Company
NCT ID: NCT07479797
Sites in California: - City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- Stanford University — Stanford, California
Phase 3 Recruiting Industry
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (C…
Sponsor: CSL Behring
NCT ID: NCT07648264
Sites in California: - UC Irvine — Orange, California
Phase 3 Recruiting Industry
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06104566
Sites in California: - Ascentage Investigative Site — Anaheim, California
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Margina…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in California: - David Geffen School of Medicine at UCLA — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07634471
Sites in California: - City of Hope - Duarte Cancer Center ( Site 1301) — Duarte, California
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Children's Hospital of Orange County — Orange, California
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope Seacliff — Huntington Beach, California
- City of Hope Antelope Valley — Lancaster, California
- City of Hope at Long Beach Elm — Long Beach, California
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in California: - UC Irvine Health Cancer Center-Newport — Costa Mesa, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UCI Health Laguna Hills — Laguna Hills, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- UCSF Medical Center-Parnassus — San Francisco, California
Phase 2 Recruiting NIH
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in California: - Hoag Family Cancer Center — Newport Beach, California
- Stanford University — Palo Alto, California